Novartis Institutes-Bio Med is categorized under Research Institute in Cambridge, MA and active since 2002.
Novartis Institutes-Bio Med was established in 2002, and today employs 1 to 4, earning Unknown per year. This is a Research Institute business, which does work in the B2B market, and is classified as a Research Institute, under code number 6215110 by the NAICS.
If you are seeking more information, feel free to contact Mark Fishman at the company’s single location by writing to 250 Massachusetts Avenue, Cambridge, Massachusetts MA 02139 or by phoning (617) 871-8000. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Novartis Institutes-Bio Med |
| Contact Person: | Mark Fishman |
| Address: | 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 |
| Phone Number: | (617) 871-8000 |
| Website Address: | nibr.novartis.com |
| Annual Revenue (USD): | Unknown |
| Founded: | 2002 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Research Institute |
| SIC Code: | 8733 |
| NAICS Code: | 6215110 |
| Share This Business: |
Novartis Institutes-Bio Med was started in 2002 to provide professional Research Institute under the SIC code 8733 and NAICS code 6215110. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of Unknown per annum.
Feel free to contact Mark Fishman for inquiries that concern Novartis Institutes-Bio Med by calling the company number (617) 871-8000, as your correspondence is most welcome. Additionally, the physical location of the single location of Novartis Institutes-Bio Med can be found at the coordinates 42.36158,-71.0974 as well as the street address 250 Massachusetts Avenue in Cambridge, Massachusetts 02139.
For its online presence, you may visit Novartis Institutes-Bio Med’s website at nibr.novartis.com and engage with its social media outlets through on Twitter and on Facebook.